CEACAM5 and cancer: Notably, these cancer antigens are prerequisite for clinical therapy design for bispecific T cell engagers (BiTES) (CD3*CEA), anti-CEA Chimeric antigen receptor T cell (CAR-T), anti-epithelia cell adhesion molecule (EPCAM) CAR-T and several others.